Literature DB >> 3363962

Piroxicam and doxepin--an alternative to narcotic analgesics in managing advanced cancer pain.

M L Cohn, A F Machado, R Bier, M Cohn.   

Abstract

To provide an effective continuum of the relief of severe carcinomatous pain with minimal side reactions, we initiated treatment with piroxicam (60 to 120 mg per day) and doxepin hydrochloride (25 to 225 mg per day). Of 30 patients presenting with severe pain of cancer of various origins, 7 continued to death with piroxicam and doxepin therapy. An additional 17 were successfully treated for 6 to 66 weeks with therapy reported here but, as disease progressed, required supplemental narcotics. The remaining six abandoned the use of piroxicam due to complications of therapy, which ranged from diarrhea to gastric perforation; serious complications were associated with patients' failure to adhere to a prescribed regimen of sucralfate. Therapy with piroxicam and doxepin proved to be safe and efficacious.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3363962      PMCID: PMC1026095     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  22 in total

1.  A validation study of the WHO method for cancer pain relief.

Authors:  V Ventafridda; M Tamburini; A Caraceni; F De Conno; F Naldi
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

2.  The use of psychotropic drugs in the treatment of cancer pain.

Authors:  R Kocher
Journal:  Recent Results Cancer Res       Date:  1984

3.  Guidelines for therapy of pain in cancer patients.

Authors:  M Zimmermann; P Drings
Journal:  Recent Results Cancer Res       Date:  1984

Review 4.  Renal syndromes associated with nonsteroidal antiinflammatory drugs.

Authors:  D M Clive; J S Stoff
Journal:  N Engl J Med       Date:  1984-03-01       Impact factor: 91.245

5.  Management of cancer pain.

Authors:  J J Bonica
Journal:  Recent Results Cancer Res       Date:  1984

6.  Side-effects of piroxicam (Feldene). A one-year material of 103 reports from Norway.

Authors:  K Laake; L Kjeldaas; C F Borchgrevink
Journal:  Acta Med Scand       Date:  1984

Review 7.  Use of non-steroidal anti-inflammatory drugs in the treatment of pain in cancer.

Authors:  V Ventafridda; C Fochi; D De Conno; E Sganzerla
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

8.  Double-blind crossover comparison of piroxicam and naproxen in the treatment of active osteoarthritis.

Authors:  R H Hodge
Journal:  Semin Arthritis Rheum       Date:  1985-02       Impact factor: 5.532

9.  The efficacy of piroxicam in comparison with sulindac in the treatment of rheumatoid arthritis.

Authors:  A D Meisel; B F Germain
Journal:  Semin Arthritis Rheum       Date:  1985-02       Impact factor: 5.532

10.  A double-blind comparative study of piroxicam and ibuprofen in the treatment of rheumatoid arthritis.

Authors:  G E McLaughlin
Journal:  Semin Arthritis Rheum       Date:  1985-02       Impact factor: 5.532

View more
  1 in total

1.  Piroxicam and doxepin in pain management.

Authors:  J Pelton
Journal:  West J Med       Date:  1988-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.